Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment

We present the results of a phase 1 study that evaluated the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary disease response to cusatuzumab, a novel anti‐CD70 monoclonal antibody, in combination with azacitidine, in newly diagnosed acute myeloid leukemia Japanese partici...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikezoe, Takayuki, Usuki, Kensuke, Aida, Kensuke, Hatayama, Tomoyoshi, Shirahase, Toru, Yamauchi, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986061/
https://www.ncbi.nlm.nih.gov/pubmed/36394119
http://dx.doi.org/10.1111/cas.15663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986061/
https://www.ncbi.nlm.nih.gov/pubmed/36394119
http://dx.doi.org/10.1111/cas.15663

Ejemplares similares